The Evolving Role of Radium-223 in mCRPC and the Impact of Combination Therapies

Video Content above is prompted by the following:

• What are the challenges, historically, that the PEACE III study addresses?
• Discuss reasons for the relatively poor uptake of radium-223 (Xofigo) in the clinic.
• Radium alone doesn’t control prostate-specific androgen (PSA), nor does docetaxel. PSA control is addressed by androgen receptor inhibitor (ARI).
• Layered radium-223 and enzalutamide plus ARI will control PSA, so radium-223 can be administered without being questioned or second-guessed.
• Similar to the ARASENS trial, maintain relationship and management and share care with med oncology for docetaxel.
• Discuss the rationale for combining radium-223 with androgen receptor–targeted therapy (enzalutamide). (Sartor et al [2018]; Shore et al [2020])
• Allows for 2 distinct mechanisms of action.